Pulmonx Corp., founded in Redwood City, US, is dedicated to developing and marketing innovative medical devices aimed at diagnosing and treating pulmonary disorders. Their core mission is to enhance the quality of life for patients with severe lung conditions through advanced, minimally invasive solutions. The company’s flagship product, the Zephyr Valve, is designed to improve breathing in patients with severe emphysema by reducing lung hyperinflation. Pulmonx operates on a global scale, focusing on providing cutting-edge pulmonary care.
Notable figures associated with Pulmonx include key investors from prominent venture capital firms such as Kleiner Perkins and NEA. The company has achieved significant milestones, including FDA approval for the Zephyr Valve and widespread adoption in leading medical centers worldwide. Pulmonx’s impact is evident in the numerous patient success stories, highlighting improved mobility and quality of life, thereby solidifying its position as a leader in pulmonary health innovation.
